Antibody, COVID-19, SARS-CoV-2, Vaccines
Conditions
Brief summary
Vaccines against the coronavirus type 2 causing severe acute respiratory syndrome Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been created in a short period of time due to the rapid spread of the virus. These vaccines use different and sometimes innovative technologies, such as the use of ribonucleic acid (RNA), or a non-replicating viral vector. Efficacy ranging from 70-90% in the first weeks after the second injection of these vaccines has been reported, with side effects whose causality remains to be determined.
Detailed description
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Interventions
None listed
Sponsors
Department of Health Affairs, Monaco
Centre Scientifique de Monaco
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Participant must live in the Principality of Monaco * Deliver a written consent to participate to the study * And/Or Have been infected with SARS-CoV-2 * And/Or Have been, or are about to be, vaccinated against SARS-CoV-2
Exclusion criteria
\- None of the above
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Covid-19 Neutralizing Antibodies Measurment | 24-month period | Inform any individual who has been infected with or vaccinated against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have about their level of immune protection, through a bi-annual follow-up |
Countries
Monaco
Contacts
Primary ContactEric VOIGLIO, MD, PhD
Backup ContactThomas ALTHAUS, MD, PhD
Outcome results
None listed